Carbidopa/levodopa GR: Ph III amended

Intec amended the ongoing, double-blind, double-dummy, U.S. Phase III Accordance Study of oral AP-CDLD to reduce enrollment to 328 patients from 460. Intec said the amendment reflects input from "key ...